Clinical Trial

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-06-01; most recent amendment 2025-06-05.
Status change: Not Yet Recruiting → Recruiting 2021-04-12
Trial Details
NCT Number NCT04412616
Lead Sponsor Changchun Intellicrown Pharmaceutical Co. LTD
Collaborators: Covance
Conditions Advanced EGFR Positive Solid Tumor
Enrollment 60 participants
Start Date 2020-09-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-07-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-10